Eye Health

Treating Eye Vein Blockages

BY National Institutes of Health TIMEAugust 12, 2022 PRINT

Fluid buildup at the back of the eye can cause swelling and leaky blood vessels. This is called macular edema. If left untreated, it can lead to blurred vision and eventually blindness. Retinal vein occlusions are one cause of it. These are blockages in veins in the retina (the light-sensing tissue in the back of your eye). A new study showed that treating blockages brings long-lasting benefits.

The study compared two drugs: aflibercept (Eylea) and bevacizumab (Avastin). Both block a family of molecules called VEGFs. VEGFs are released when blood flow is disrupted, leading to macular edema.

Researchers treated 330 people with macular edema caused by severe retinal vein blockages. Participants received an injection with an anti-VEGF drug once a month for at least six months. After one year, participants continued treatments at their doctor’s discretion.

The research team assessed participants five years after their initial treatment. They found that most doctors reduced the frequency of injections after 12 months. Some switched their patients to the other anti-VEGF drug. After five years, many showed improvement in the sharpness of their vision compared with the start of the study. Both drugs had similar results.

“This five-year study tells us a lot about what’s happening with retinal vein occlusion patients in the real world,” says Dr. Ingrid U. Scott of Penn State University. “It also underscores the importance of disease monitoring and individualized treatment to achieve the best possible vision.”

References

Month 60 outcomes after treatment initiation with anti-VEGF therapy for macular edema due to central or hemi-retinal vein occlusion. Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA; SCORE2 Investigator Group.Am J Ophthalmol.2022 Apr 21:S0002-9394(22)00144-1. doi: 10.1016/j.ajo.2022.04.001. Online ahead of print. PMID: 35461831.

A part of the U.S. Department of Health and Human Services, NIH is the largest biomedical research agency in the world.
You May Also Like